STAT3 and T-cell non-Hodgkin lymphoma: Given that STAT3 activation is such a prevalent feature in mature T cell lymphomas and that there are multiple mechanisms driving its phosphorylation and activation of downstream targets, these studies provide a plethora of potential therapeutic targets.